Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | CASP6 | P55212 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.56 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8302596 | 0.92 | CASP6 (0.60) | HTTKMT2APKMCASP6LMNA | |
| SCHEMBL8299130 | 0.81 | CASP6 (0.51) | HTTKMT2APKMCASP6LMNA | |
| SCHEMBL3364018 | 0.74 | MAPT (0.62) | KMT2ALMNAMAPTHPGDALDH1A1 | |
| SCHEMBL3364021 | 0.74 | MAPT (0.62) | KMT2ALMNAMAPTHPGDALDH1A1 | |
| SCHEMBL18958907 | 0.74 | PKM (0.70) | HTTKMT2APKMLMNAMAPT | |
| SCHEMBL3369096 | 0.73 | OXTR (0.74) | KMT2ALMNAMAPTHPGDHCRTR1 | |
| SCHEMBL3366536 | 0.73 | OXTR (0.74) | KMT2ALMNAMAPTHPGDHCRTR1 | |
| SCHEMBL18958914 | 0.73 | PKM (0.68) | HTTPKMLMNAMAPTHPGD | |
| SCHEMBL21033437 | 0.73 | PKM (0.67) | HTTKMT2APKMLMNAMAPT | |
| SCHEMBL21033375 | 0.72 | PKM (0.66) | KMT2APKMLMNAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037785-A1 | Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037785-A1 | Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| WO-2005037779-A2 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS USED FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES | IMTM GMBH (DE) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037785-A1 | Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases | DNPEP, PREP, DPP4 | HTT 1551/4885KMT2A 4135/4885PKM 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.